ChAdOx1 nCoV-19疫苗长期安全性与免疫应答随访
本研究前瞻性随访了ChAdOx1 nCoV-19疫苗早期临床试验参与者,其中多人后续接种了英国新冠疫苗。2021年9月至2022年4月共纳入4470人,中位随访11.77个月,记录严重不良事件和特殊关注不良事件,未发现新发安全信号,但强调需持续上市后监测。
要点
- 中位随访11.77个月,4470人中195人报告174例SAE和71例AESI,含5例死亡。
- 未发现新发安全信号,但需持续上市后监测,尤其关注神经系统疾病。
- 小部分参与者免疫学数据显示抗三聚体SARS-CoV-2刺突蛋白总IgG呈上升趋势。
核心结论
- 未检测到新发安全信号,但持续上市后监测仍至关重要,尤其是对神经系统疾病。
研究设计与样本
- 前瞻性研究,纳入ChAdOx1 nCoV-19疫苗首批临床试验参与者,其中多人后续在英国疫苗接种规划中接种了新冠疫苗。
- 2021年9月至2022年4月共纳入4470名参与者,58%为女性,中位年龄50岁;3845/4470(86.0%)完成研究。
- 中位随访11.77个月,总随访48,116人月;记录严重不良事件(SAE)和特殊关注不良事件(AESI),AESI依据Brighton Collaboration定义选择。
主要发现
- 195名参与者中共记录174例SAE和71例AESI(33例事件同时计入两者),包括5例死亡。
- 仅小部分参与者有免疫学数据,抗三聚体SARS-CoV-2刺突蛋白总IgG在研究期间呈上升趋势。
临床怎么用
- 可为已接种ChAdOx1 nCoV-19疫苗人群的长期安全性咨询提供参考,但仍需持续上市后监测,尤其关注神经系统疾病。
局限性
- 免疫学数据仅来自小部分参与者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Follow-up of pre-licensure trial participants potentially informs a vaccine's long-term safety profile. DESIGN: This prospective study enrolled participants from the first clinical trials of ChAdOx1 nCoV-19 vaccine, many of whom subsequently received COVID-19 vaccines in the UK vaccination programme. Serious adverse events (SAEs) and adverse events of special interest (AESIs) were captured. AESI selection was based on Brighton Collaboration definitions. RESULTS: Between September 2021 and April 2022, 4470 participants enrolled (58% female, median age 50 years); 3845/4470 (86.0%) completed the study. Median follow-up was 11.77 months; total follow-up was 48,116 person-months. There were 174 SAEs and 71 AESIs (33 events recorded as both) in 195 participants, including 5 deaths. Immunology data were available for a small subset of participants; total IgG against trimeric SARS-CoV-2 spike protein tended to increase during the study. CONCLUSIONS: Although no emergent safety signals were detected, continued post-marketing surveillance remains imperative, particularly for neurological disorders. EUDRACT NUMBER: 2021-003382-36.
引用
- Ebrahimi N, de Whalley P, Kanji N, et al. ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses. Vaccine. 2026. PMID: 42472497. doi:10.1016/j.vaccine.2026.128951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。